Treatment of hypertension in aviators: a clinical trial with Aldactazide.
Thirty-two USAF aircrewmen with mild or moderate, uncomplicated essential hypertension were treated with Aldactazide (spironolactone and hydrochlorothiazide). The study was designed to determine the efficacy and safety of this drug combination in aircrew subject to the stress of flying high-performance aircraft. All patients were investigated in detail before, and again 6 weeks after, beginning Aldactazide treatment. Adequate blood pressure control was achieved in 94% of patients; 84% were able to return to flying duties. Treatment was associated with a moderate loss of weight and plasma volume, and a slight reduction in renal function. Tolerance to multiple stress tests was unimpaired after treatment. Symptoms attributable to treatment were minimal. We conclude that in the dose used, four tablets or less daily, Aldactazide is a safe and fairly effective secondline treatment for hypertensive aircrewmen.
D000328:Adult; D000337:Aerospace Medicine; D001810:Blood Volume / Q000187:drug effects; D004338:Drug Combinations; D004573:Electrolytes / Q000097:blood; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D013148:Spironolactone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013312:Stress, Physiological
D004338:Drug Combinations; D004573:Electrolytes; C016210:buthiazide, spironolactone drug combination; D006852:Hydrochlorothiazide; D013148:Spironolactone